We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Y
Collaco Moraes
y.collaco-moraes@ucl.ac.uk
Dr
Sarah
Pett
s.pett@ucl.ac.uk
MRC CTU
FLUSTUDIES
mrcctu.flustudies@ucl.ac.uk
Other viral diseasesProvisional assignment of new diseases of uncertain etiologyInfluenza and pneumonia
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prospective follow-up studies of people who develop influenza or infection with novel noninfluenza respiratory viruses are critical to gaining an understanding of the severity and risk factors for these conditions. The impetus for this research in INSIGHT was when a novel H1N1 influenza A virus began spreading among people throughout the world in the spring of 2009 as the first pandemic of influenza in the last 40 years.1 It was considered critical to have studies that could not only reliably characterize people with 2009 H1N1 virus infection but to also characterize the virus and the outcomes of the infection in a prospective manner.
While 2009 H1N1 virus is now co-circulating worldwide as a seasonal influenza A virus, many lessons were learned during the 2009 H1N1 pandemic about the importance of having a world-wide infrastructure in place to understand the severity and risk factors for novel respiratory viruses that could result in major pandemics. In addition to many questions remaining about seasonal influenza, it is important to be able to characterize individuals who are infected with novel respiratory viruses such as Middle East Respiratory Syndrome Coronavirus (MERS-CoV)3,4 or Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).5 The data collected could help inform patient management and policy decisions in relation to the threat of future pandemics. Thus, for this version of the protocol the inclusion criteria have been broadened to ensure that participants hospitalized with novel respiratory viruses, that have been identified as very important from a public health point of view, are enrolled and followed as well as individuals hospitalized with influenza.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Current imprisonment, or compulsory detention (involuntary incarceration) for treatment of a psychiatric or physical illness
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Y
Collaco Moraes
y.collaco-moraes@ucl.ac.uk
Dr
Sarah
Pett
s.pett@ucl.ac.uk
MRC CTU
FLUSTUDIES
mrcctu.flustudies@ucl.ac.uk
The study is sponsored by University of Minnesota (USA) and funded by National Institute of Allergy and Infectious Diseases (NIH NIAID) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 7990
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
